Acadia Pharmaceuticals Inc
ACAD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001070494
In the last 90 days, Acadia Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 354 institutions reported holding it in 13F filings for Q2 2026, worth $4.27B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:39 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Feb 26, 2025 | Feb 27, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Revenue | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M |
| Cost of revenue | $89.0M | $81.8M | $41.6M | $10.2M | $10.8M |
| Gross profit | – | – | $684.8M | $507.1M | $473.3M |
| Research and development | $328.8M | $303.2M | $351.6M | $361.6M | $239.4M |
| Selling, general and administrative | $548.9M | $488.4M | $406.6M | $369.1M | $396.0M |
| Operating income | $104.8M | $230.8M | -$73.4M | -$223.6M | -$170.4M |
| Income tax | -$252.1M | $31.6M | $10.3M | $2.53M | $351.0K |
| Net income | $391.0M | $226.5M | -$61.3M | -$216.0M | -$167.9M |
| EPS, basic | $2.32 | $1.37 | $-0.37 | $-1.34 | – |
| EPS, diluted | $2.30 | $1.36 | $-0.37 | $-1.34 | – |
| Weighted shares, basic | 168.4M | 165.7M | 163.8K | 161.7K | – |
| Weighted shares, diluted | 169.9M | 166.4M | 163.8K | 161.7K | – |
| Margins and growth | |||||
| Gross margin | – | – | 94.3% | 98.0% | 97.8% |
| Operating margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Net margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% |
| Revenue growth, year over year | +11.9% | +31.8% | +40.4% | +6.8% | +9.6% |
| Net income growth, year over year | +72.7% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Feb 26, 2025 | Feb 27, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Cash and equivalents | $177.7M | $319.6M | $188.7M | $114.8M | $147.4M |
| Accounts receivable | $121.5M | $98.7M | $98.3M | $62.2M | $64.4M |
| Inventory | $111.4M | $91.7M | $40.4M | $11.6M | $14.1M |
| Total current assets | $1.06B | $938.3M | $616.1M | $507.9M | $617.8M |
| Property, plant and equipment | $7.51M | $4.21M | $4.61M | $6.02M | $8.05M |
| Intangible assets | $108.9M | $119.8M | $65.5M | – | $0 |
| Total assets | $1.56B | $1.19B | $749.0M | $587.8M | $700.1M |
| Accounts payable | $10.9M | $16.2M | $17.5M | $12.7M | $6.88M |
| Total current liabilities | $277.1M | $394.9M | $254.3M | $125.6M | $96.1M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M |
| Shareholders' equity | $1.23B | $732.8M | $431.8M | $400.4M | $540.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Feb 26, 2025 | Feb 27, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Operating cash flow | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M |
| Capital expenditures | $4.69M | $523.0K | $50.0K | $0 | $1.12M |
| Free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M |
| Stock-based compensation | $52.1M | $67.0M | $66.4M | $68.2M | $63.6M |
| Investing cash flow | -$302.6M | -$30.5M | $32.0M | $73.2M | -$71.1M |
| Financing cash flow | $49.9M | $6.84M | $25.1M | $8.20M | $18.2M |
| Net change in cash | -$142.8M | $133.9M | $73.8M | -$32.6M | -$178.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.9% | 7.0% | 9.1% | 13.2% | 13.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 28, 2026 | 172.8M | +2.2% | SEC |
| Jul 28, 2026 | 172.3M | +2.1% | SEC |
| Apr 29, 2026 | 171.2M | +2.3% | SEC |
| Feb 18, 2026 | 170.5M | +2.2% | SEC |
| Oct 29, 2025 | 169.2M | +1.7% | SEC |
| Jul 30, 2025 | 168.7M | +1.7% | SEC |
| Apr 30, 2025 | 167.4M | +1.3% | SEC |
| Feb 18, 2025 | 166.8M | +1.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.